Literature DB >> 2845294

Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields.

R Bashir1, F Hochberg, R Oot.   

Abstract

Recognition of the local nature of glioblastoma has generated an increasing interest in treatment using radioactive implants (interstitial brachytherapy). A key issue in such implantation is the configuration of the radiation field in relation to the resected tumor. In particular, should radiation be provided to the area from which the tumor has been resected? To clarify this issue, we evaluated patterns of tumor regrowth into this resected area in 62 patients. Three patterns of computed tomographic scan-documented tumor regrowth were recognized: preferential (regrowth to refill the resected area only), circumferential (regrowth into the resected area and previously uninvolved contiguous brain) and away (local regrowth into noncontiguous brain, sparing the surgical bed). Regrowth of the tumor 6.3 to 6.8 months after resection was seen in 59 of 62 patients (95.2%). Preferential regrowth was seen in 32 of 62 patients (51.6%), and circumferential regrowth was seen in 27 of 62 patients (43.5%). Regrowth away was seen in 3 of 62 patients (4.8%). Radiation fields planned for interstitial brachytherapy must adequately include the resected area because of the high incidence of tumor regrowth into that area.

Entities:  

Mesh:

Year:  1988        PMID: 2845294     DOI: 10.1227/00006123-198807000-00006

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  22 in total

1.  Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma.

Authors:  J A Williams; L E Dillehay; K Tabassi; E Sipos; C Fahlman; H Brem
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

Review 2.  Interstitial laser thermotherapy in neurosurgery: a review.

Authors:  T Menovsky; J F Beek; M J van Gemert; F X Roux; S G Bown
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 3.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

4.  Radiation treatment parameters for re-irradiation of malignant glioma.

Authors:  M Niyazi; M Söhn; S B Schwarz; P Lang; C Belka; U Ganswindt
Journal:  Strahlenther Onkol       Date:  2012-02-22       Impact factor: 3.621

5.  Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.

Authors:  Pilar de la Puente; Nicole Fettig; Micah J Luderer; Abbey Jin; Shruti Shah; Barbara Muz; Vaishali Kapoor; Sreekrishna M Goddu; Noha Nabil Salama; Christina Tsien; Dinesh Thotala; Kooresh Shoghi; Buck Rogers; Abdel Kareem Azab
Journal:  J Pharm Sci       Date:  2017-11-21       Impact factor: 3.534

6.  Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma.

Authors:  C Cirielli; K Inyaku; M C Capogrossi; X Yuan; J A Williams
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

7.  Interstitial brachytherapy for low-grade cerebral gliomas: analysis of results in a series of 36 cases.

Authors:  M Scerrati; P Montemaggi; M Iacoangeli; R Roselli; G F Rossi
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas.

Authors:  Joshua T McKenzie; Jess N Guarnaschelli; Achala S Vagal; Ronald E Warnick; John C Breneman
Journal:  J Neurooncol       Date:  2013-04-16       Impact factor: 4.130

9.  Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas.

Authors:  T Wehbe; M Glantz; H Choy; L Glantz; S Cortez; W Akerley; P Mills; B Cole
Journal:  J Neurooncol       Date:  1998-09       Impact factor: 4.130

10.  Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times.

Authors:  C Goetz; P Riva; G Poepperl; F J Gildehaus; A Hischa; K Tatsch; H J Reulen
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.